The nation of Zimbabwe has declined a significant American healthcare agreement worth 367 million US dollars (£272m) over five years because of Washington's demand for confidential biological samples.
The decision was revealed following a official document from December was disclosed, revealing that President Emmerson Mnangagwa felt the arrangement was "lopsided".
A government representative has since stated that the US was requesting health data for research and profit but was unwilling to share the benefits from any future treatments.
"We will now turn to the difficult and regrettable process of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had provided over $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged more talks to reach a deal agreeable to both sides so the country's vital HIV treatment initiative can continue.
Wider Implications
This rejection comes after a comparable situation in neighbouring Kenya, where a court suspended a related health funding agreement after legal challenges were raised about the security of citizens' medical information.
Since returning to office last year, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had managed aid for the US government, but Trump argued its expenditure was "wasteful" and his government was pursuing direct bilateral agreements to boost openness and accountability.
Based on reports, Sixteen nations in Africa have so far agreed to these new health pacts, constituting over $18.3bn of fresh investment.
Details of the Declined Deal
The funds for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this cooperation could have provided immense benefits for Zimbabwean communities, especially the 1.2 million currently receiving HIV treatment through US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana said the proposed deal was "asymmetrical".
"Our nation was requested to provide its biological resources and data indefinitely, with no corresponding promise of benefiting from any medical innovations – such as new medicines or tests – that might result from that provided information," Mangwana explained.
"Effectively, our country would supply the basic resources for medical research with no certainty that the final treatments would be accessible to our population should a new health crisis emerge."
Sovereignty and Global Health
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were upending systems previously set up through the global health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme designed to manage future pandemics.
"This system is designed to ensure that when a country provides its samples, the benefits – including vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the resources to develop them."
These objections over the US deal "should not be misconstrued as hostility towards the US," he added.
"We welcome ongoing dialogue with our American counterparts on how future collaboration could be arranged in a way that honours the independence and interests of each country."
Health Experts Response
Medical experts expressed it acknowledged the government's concerns, but urged that negotiations should continue considering much of the country's Aids initiatives relied on external financing.
"If specific concerns exist, such as those involving data governance or agreement terms, these can often be resolved via detailed discussion and mutually agreed protections," the group said.
The halted deal underscores the complex debate between accepting crucial international aid and protecting national sovereignty in an increasingly interconnected world.